Graduate School of Medical Sciences
A partnership with the Sloan Kettering Institute

Gabriela Chiosis

Our focus lies in comprehending how internal and external stressors intricately contribute to diseases, negatively affecting cells, tissues, and organisms. Through studying their impact on biology, we strive to discover treatments and diagnostics.


Human diseases have a multifaceted origin involving internal and external factors that disrupt cells, tissues, organs, and organisms. These disruptive agents, referred to as stressors, can be acute or chronic, and their effects on biological systems are complex. The response to stressors, whether it leads to adaptation or maladaptation, is influenced by factors such as the duration, intensity, predictability, and controllability of the stressors, as well as genetic and environmental factors. To develop realistic drugs and therapies that target the intricate and biologically relevant networks underlying diseases, a shift in perspective, away from the unitary protein approach, is required. Particularly, protein-protein interaction (PPI) networks play a vital role in this context as they encode and execute the flux of information linking stressors to phenotype at the cellular level. As cells do not function in isolation, the effect of PPI networks reverberates and extends beyond individual cells, and into tissue and whole organism levels. The disease PPI network, which represents the alterations in cellular PPIs caused by stressors and their impact on the system, becomes a target for therapeutic interventions. From a network standpoint, proteins are not treated as isolated entities but rather as interconnected elements whose significance is defined by the number and structure of their connections within the network.  

To effectively combat diseases, it is thus crucial to comprehend and leverage the unique biological networks that arise from the interplay between genetic and environmental stressors. This necessitates moving away from a reductionist approach focused solely on individual proteins and instead targeting the specific dysfunctions within context-specific PPI networks. The primary objective of the Chiosis lab is to gain insights into such disease-causing dysfunctions within PPI networks, ultimately identifying, targeting, and manipulating these dysfunctions to achieve therapeutic efficacy and enable precision medicine. By understanding how stressors disrupt PPI networks and the resulting system perturbations, we aim to uncover potential targets for therapeutic intervention. This knowledge can lead to more effective and tailored treatments for complex diseases such as cancers and neurodegenerative disorders. 



Trained as a chemist and having graduated from Columbia University with a Ph.D. in organic chemistry, Dr. Chiosis spent the first part of her career discovering and developing chemical probes and drugs. Albeit successful, with each of these being a pioneering chemical never made by man or nature, and with most licensed as drug development candidates or diagnostics, she became dissatisfied with how little the processes these drugs were meant to treat were actually known. Consequently, the goal of her current research is to bridge the gap between chemical innovation and comprehensive understanding of disease mechanisms. 

  • Selected as one of Sloan Kettering Institute’s 10 Noteworthy Science Breakthroughs of 2021
  • Selected as one of the Academic Drug Discovery Consortium (ADDC) - Women Bioentrepreneurs of 2022 
  • Discovered and translated to clinic two drug candidates (i.e., zelavespib and icapamespib), several imaging diagnostics (i.e., 124I-PU-H71 PET, 124I-PU-AD PET) and methods of treatment
  • Research from Chiosis lab featured in numerous News pieces and editor’s picks and selected for the cover of several journal issues

Current Areas of Focus

Need more info?
Ask a question
Follow us on

Weill Cornell Medicine Graduate School of Medical Sciences 1300 York Ave. Box 65 New York, NY 10065 Phone: (212) 746-6565 Fax: (212) 746-8906